Multidrug-Resistant Tuberculosis in U.S.-Bound Immigrants and Refugees
Authors:
Open Access
- 1 June 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 19 (6) , 943-951
Abstract
Rationale: Approximately two-thirds of new cases of tuberculosis (TB) in the United States are among non–U.S.-born persons. Culture-based overseas TB screening in U.S.-bound immigrants and refugees has substantially reduced the importation of TB into the United States, but it is unclear to what extent this program prevents the importation of multidrug-resistant TB (MDR-TB). Objectives: To study the epidemiology of MDR-TB in U.S.-bound immigrants and refugees and to evaluate the effect of culture-based overseas TB screening in U.S.-bound immigrants and refugees on reducing the importation of MDR-TB into the United States. Methods: We analyzed data of immigrants and refugees who completed overseas treatment for culture-positive TB during 2015–2019. We also compared mean annual number of MDR-TB cases in non–U.S.-born persons within 1 year of arrival in the United States between 1996–2006 (when overseas screening followed a smear-based algorithm) and 2014–2019 (after full implementation of a culture-based algorithm). Results: Of 3,300 culture-positive TB cases identified by culture-based overseas TB screening in immigrants and refugees during 2015–2019, 122 (3.7%; 95% confidence interval [CI], 3.1–4.1) had MDR-TB, 20 (0.6%; 95% CI, 0.3–0.9) had rifampicin-resistant TB, 382 (11.6%; 95% CI, 10.5–12.7) had isoniazid-resistant TB, and 2,776 (84.1%; 95% CI, 82.9–85.4) had rifampicin- and isoniazid-susceptible TB. None were diagnosed with extensively drug-resistant TB. All 3,300 persons with culture-positive TB completed treatment overseas; of 70 and 11 persons who were treated overseas for MDR-TB and rifampicin-resistant TB, respectively, none were diagnosed with TB disease at postarrival evaluation in the United States. Culture-based overseas TB screening in U.S.-bound immigrants and refugees prevented 24.4 MDR-TB cases per year from arriving in the United States, 18.2 cases more than smear-based overseas TB screening. The mean annual number of MDR-TB cases among non–U.S.-born persons within 1 year of arrival in the United States decreased from 34.6 cases in 1996–2006 to 19.5 cases in 2014–2019 (difference of 15.1; P < 0.001). Conclusions: Culture-based overseas TB screening in U.S.-bound immigrants and refugees substantially reduced the importation of MDR-TB into the United States.Keywords
This publication has 30 references indexed in Scilit:
- National Survey of Drug-Resistant Tuberculosis in ChinaNew England Journal of Medicine, 2012
- Estimating the Impact of Newly Arrived Foreign-Born Persons on Tuberculosis in the United StatesPLOS ONE, 2012
- MDR Tuberculosis — Critical Steps for Prevention and ControlNew England Journal of Medicine, 2010
- Multidrug- and Extensively Drug-resistant Tuberculosis in Africa and South America: Epidemiology, Diagnosis and Management in Adults and ChildrenClinics in Chest Medicine, 2009
- Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and ControlClinics in Chest Medicine, 2009
- Overseas Screening for Tuberculosis in U.S.-Bound Immigrants and RefugeesNew England Journal of Medicine, 2009
- Multidrug-Resistant Tuberculosis Outbreak among US-bound Hmong Refugees, Thailand, 2005Emerging Infectious Diseases, 2008
- Multidrug-resistant and extensively drug-resistantMycobacterium tuberculosis: epidemiology and controlExpert Review of Anti-infective Therapy, 2007
- Assessing the Performance of Overseas Tuberculosis Screening ProgramsArchives of internal medicine (1960), 2006
- Overseas Screening for Tuberculosis in Immigrants and Refugees to the United States: Current StatusClinical Infectious Diseases, 1996